In a 56-year-old man three months after myocardial infarction who has quit smoking, with normotensive blood pressure and elevated LDL cholesterol, what is the appropriate management?

Immediate Lipid-Lowering Therapy Required

This patient requires immediate initiation or intensification of lipid-lowering therapy with a high-intensity statin (Answer C). With an LDL of 5.3 mmol/L (approximately 205 mg/dL) three months post-MI, this patient is dramatically above target and at very high risk for recurrent cardiovascular events.

Why Lipid-Lowering Therapy is the Priority

This patient has established atherosclerotic cardiovascular disease (ASCVD) following myocardial infarction. The most recent 2024 International Lipid Expert Panel guidelines 1 explicitly state that post-ACS patients should achieve LDL-C <1.4 mmol/L (<55 mg/dL). This patient's current LDL of 5.3 mmol/L is nearly 4 times higher than the target.

The Evidence is Unequivocal

Multiple ACC/AHA guidelines 2 provide Class I recommendations (highest level) that:

• All post-MI patients with LDL ≥100 mg/dL should be prescribed statin therapy at hospital discharge (Level of Evidence: A)
• Even patients with LDL <100 mg/dL should receive statins post-MI (Level of Evidence: B)
• The target LDL should be "substantially less than 100 mg/dL" - older guidelines from 2004 2
• Current targets are even more aggressive at <55 mg/dL 1

Recommended Treatment Algorithm

Step 1: Immediate High-Intensity Statin

• Start atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily 1
• If baseline LDL is very high (as in this case), consider starting combination therapy with statin + ezetimibe 10 mg immediately 1

Step 2: Reassess at 4-6 Weeks

• Check LDL-C levels
• If LDL remains >1.4 mmol/L (>55 mg/dL), add ezetimibe 10 mg if not already prescribed 1

Step 3: Further Intensification if Needed (at 4-6 weeks after ezetimibe)

• If LDL still >1.4 mmol/L on maximal statin + ezetimibe, consider adding:
  • Bempedoic acid 180 mg daily 1, or
  • PCSK9 inhibitors (alirocumab or evolocumab) 1, 3

Why Not the Other Options?

Blood Pressure (Option A)

The patient's BP is 137/84 mmHg. While the 2004 ACC/AHA guidelines 2 recommend BP <140/90 mmHg for most post-MI patients, this patient is essentially at goal. The guidelines state that BP medications should be added when BP is ≥140/90 mmHg 2. Lifestyle modifications are appropriate for BP 120-139/80-89 mmHg 2, but the immediate priority is the severely elevated LDL.

Exercise and Diet Alone (Option B)

While lifestyle modifications are absolutely essential and should be implemented 2, they are insufficient as monotherapy when LDL is this elevated. The guidelines are explicit: dietary therapy should include <7% calories from saturated fat and <200 mg/day cholesterol 2, and regular physical activity (30-60 minutes daily or at least 3-4 times weekly) should be encouraged 2. However, with LDL at 5.3 mmol/L, pharmacotherapy cannot be delayed - it must be initiated immediately alongside lifestyle changes.

Critical Clinical Pitfalls

1. Do not wait to "try diet and exercise first" - this patient is 3 months post-MI with dangerously elevated LDL. Every day without adequate lipid control increases recurrent event risk.

2. Do not undertreated with moderate-intensity statins - this patient needs high-intensity therapy, potentially with combination therapy from the start given the baseline LDL level 1.

3. Ensure proper follow-up - The 2024 guidelines 1 emphasize structured discharge letters specifying LDL targets, treatment escalation plans, and monitoring schedules at 4-6 week intervals.

4. Address statin adherence - Recent data 4 shows that 35% of post-MI patients discontinue or irregularly use statins within the first year, which is the primary reason for failure to achieve LDL targets.

The Mortality and Morbidity Impact

Early statin trials demonstrated 25% reduction in nonfatal MI and 14% reduction in fatal MI with cholesterol lowering 2. Modern high-intensity statin therapy with ezetimibe (IMPROVE-IT trial) showed additional 7% relative risk reduction in ASCVD events 3. PCSK9 inhibitor trials (FOURIER and ODYSSEY OUTCOMES) demonstrated 15% relative risk reduction in composite ASCVD events 3.

The number needed to treat for achieving LDL <1.4 mmol/L to prevent recurrent MI, stroke, or death is approximately 115 5, making this intervention highly cost-effective and clinically meaningful.